This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OPTN OptiNose (OPTN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsBuy This Stock About OptiNose Stock (NASDAQ:OPTN) 30 days 90 days 365 days Advanced Chart Get OptiNose alerts:Sign Up Key Stats Today's Range$9.60▼$9.6050-Day Range$9.38▼$9.7152-Week Range$4.82▼$17.18VolumeN/AAverage Volume63,682 shsMarket Capitalization$97.22 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingHold Company Overview OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. Read More OptiNose Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks16th Percentile Overall ScoreOPTN MarketRank™: OptiNose scored higher than 16% of companies evaluated by MarketBeat, and ranked 897th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingOptiNose has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageOptiNose has received no research coverage in the past 90 days.Read more about OptiNose's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OptiNose are expected to grow in the coming year, from ($3.22) to ($2.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptiNose is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptiNose is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for OPTN. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOptiNose does not currently pay a dividend.Dividend GrowthOptiNose does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-2.10 Short InterestThere is no current short interest data available for OPTN. News and Social MediaN/ANews SentimentN/A Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, OptiNose insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.30% of the stock of OptiNose is held by insiders.Percentage Held by Institutions85.60% of the stock of OptiNose is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OptiNose's insider trading history. Receive OPTN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptiNose and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OPTN Stock News HeadlinesParatek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty TherapiesMay 21, 2025 | finance.yahoo.comOptinose Stockholders Approve Merger with ParatekMay 16, 2025 | tipranks.com"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That's why we've rushed to update our book "Crypto Revolution" – to show you exactly how to position yourself for this historic opportunity. | Crypto 101 Media (Ad)OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTNApril 29, 2025 | businesswire.comOptinose Reports 2024 Financial Results, Highlights Prescription Growth and First Operational IncomeMarch 28, 2025 | msn.comOptinose reports Q4 EPS (3c) vs ($1.33) last yearMarch 27, 2025 | markets.businessinsider.comOptinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational HighlightsMarch 26, 2025 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GB, RDFN, PRA, OPTN on Behalf of ShareholdersMarch 25, 2025 | morningstar.comMSee More Headlines OPTN Stock Analysis - Frequently Asked Questions How were OptiNose's earnings last quarter? OptiNose, Inc. (NASDAQ:OPTN) issued its earnings results on Tuesday, May, 13th. The company reported ($1.01) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by $0.27. The company earned $18.51 million during the quarter, compared to analysts' expectations of $17.70 million. When did OptiNose's stock split? OptiNose shares reverse split before market open on Tuesday, December 31st 2024.The 1-15 reverse split was announced on Thursday, December 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did OptiNose IPO? OptiNose (OPTN) raised $101 million in an initial public offering on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO. What other stocks do shareholders of OptiNose own? Based on aggregate information from My MarketBeat watchlists, some other companies that OptiNose investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), GE Aerospace (GE), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET) and Adobe (ADBE). Company Calendar Last Earnings5/13/2025Today9/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OPTN CIK1494650 Webwww.optinose.com Phone(267) 364-3500FaxN/AEmployees190Year FoundedN/APrice Target and Rating Average Price Target for OptiNose$9.00 High Price Target$9.00 Low Price Target$9.00 Potential Upside/Downside-6.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($3.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$35.48 million Net Margins-41.16% Pretax Margin-41.16% Return on EquityN/A Return on Assets-27.42% Debt Debt-to-Equity RatioN/A Current Ratio0.79 Quick Ratio0.72 Sales & Book Value Annual Sales$81.86 million Price / Sales1.19 Cash FlowN/A Price / Cash FlowN/A Book Value($11.56) per share Price / Book-0.83Miscellaneous Outstanding Shares10,127,000Free Float9,829,000Market Cap$97.22 million OptionableNot Optionable Beta-0.88 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:OPTN) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptiNose, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptiNose With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.